A revolutionary annual HIV prevention injection has successfully passed an early-stage safety trial, marking a significant advancement in HIV prevention. The study, published in The Lancet medical journal, highlights the potential of lenacapavir—a drug that prevents the virus from replicating inside human cells—as a game-changing pre-exposure prophylaxis (PrEP) option.
If future trials confirm its safety and effectiveness, lenacapavir could become the longest-acting HIV prevention method available, offering a vital alternative to existing daily pills and bi-monthly injections.
Addressing Barriers to HIV Prevention
Currently, individuals at risk of HIV can take daily PrEP tablets or receive an injection every eight weeks. While highly effective, adherence to a daily regimen can be challenging, making long-acting solutions particularly valuable.
According to the latest data from the World Health Organization (WHO), approximately 39.9 million people worldwide are living with HIV, with 65% of cases in the African region. As part of the global strategy to end the HIV epidemic by 2030, organizations such as WHO, the Global Fund, and the Joint United Nations Programme on HIV/AIDS (UNAIDS) have prioritized improving access to preventive treatments like PrEP.
Promising Trial Results
The early-stage trial involved 40 HIV-negative participants who received a single intramuscular injection of lenacapavir. Researchers reported no major safety concerns or significant side effects, and traces of the drug remained detectable in the body for more than 56 weeks—a promising sign for its potential as a once-a-year preventive measure.
Speaking at the 2025 Conference on Retroviruses and Opportunistic Infections, researchers emphasized the need for broader and more diverse clinical trials to confirm the injection’s long-term safety and efficacy. However, they noted, “Yearly dosing of lenacapavir has the potential to further decrease current barriers to PrEP by increasing uptake, persistence, and scalability.”
A Step Towards Equitable Access
Experts in the field have welcomed the breakthrough, citing its potential to transform HIV prevention efforts. Richard Angell, from the UK-based Terrence Higgins Trust HIV charity, called the findings “as exciting as they are transformational.”
“PrEP as a daily pill has been a game-changer in our HIV response. The prospect of ‘safe’ annual injectable PrEP could revolutionize access to prevention,” Angell said.
However, he also raised concerns about existing inequalities in PrEP access.
“The oral pill is still not available in prisons, online, or in community pharmacies. And while Scotland has approved bi-monthly PrEP injections, we are still awaiting NICE (National Institute for Health and Care Excellence) approval for use in England.”
The Future of HIV Prevention
As clinical trials for lenacapavir continue, public health advocates stress the importance of preparing for its potential rollout. Adequate funding for sexual health services and policy reforms to ensure equitable access will be crucial in maximizing the impact of this breakthrough.
With the possibility of a once-a-year injection for HIV prevention, the global fight against HIV/AIDS is on the brink of a significant leap forward—one that could redefine the landscape of HIV prevention for millions worldwide.
